COSMOS Pharmaceutical (3349) Q1 2027 earnings summary

Executive summary

• Q1 FY2027 net sales rose 5.2% YoY to ¥286,653 million; operating profit rose 3.1% to ¥12,005 million and profit attributable to owners of parent rose 1.0% to ¥8,251 million.

• Store expansion and low-cost operations supported results amid inflation, yen weakness and Middle East-related oil supply concerns.

Financial highlights

• Gross profit increased to ¥62,129 million from ¥57,174 million; SG&A rose to ¥50,124 million from ¥45,529 million.

• EBITDA was ¥17,911 million, up 5.7% YoY; ordinary profit was ¥12,766 million, up 4.7%.

• Extraordinary losses totaled ¥407 million, including ¥204 million from disaster losses and ¥91 million from store closings.

Outlook and guidance

• FY2027 guidance remains unchanged: net sales ¥1,190,000 million (+8.2%), operating profit ¥43,000 million (+1.5%), ordinary profit ¥45,700 million (+2.4%) and parent profit ¥30,700 million (-4.2%).

• H1 guidance: net sales ¥582,700 million (+8.5%), operating profit ¥20,780 million (+0.5%), ordinary profit ¥22,180 million (+1.1%) and parent profit ¥14,480 million (-1.2%).

• FY2027 forecast EPS is ¥387.35; H1 forecast EPS is ¥182.70. Forecasts are subject to risks and assumptions, and actual results may differ significantly.